<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164176</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0542</org_study_id>
    <secondary_id>YONSEI-CRAD001CKR12T</secondary_id>
    <secondary_id>KCSG-HN-10-03</secondary_id>
    <nct_id>NCT01164176</nct_id>
  </id_info>
  <brief_title>Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer</brief_title>
  <official_title>An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well everolimus works in treating patients with
      locally advanced or metastatic thyroid cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate response rate in patients with locally advanced or metastatic, unresectable
           or refractory thyroid cancer treated with everolimus.

      Secondary

        -  To evaluate overall survival of these patients treated with everolimus.

        -  To evaluate progression-free survival of these patients.

        -  To evaluate toxicity of this therapy in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in
      the absence of disease progression or unacceptable toxicity.

      Blood samples are collected periodically for correlative studies.

      After completion of study treatment, patients are followed up for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>every 3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>participants will be followed until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>participants will be followed until disease progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>participants will be followed until disease progression or death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>RAD001 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>RAD001 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>RAD001 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed thyroid cancer

               -  Progressive or refractory disease within the past 6 months

               -  Locally advanced or metastatic disease

          -  Measurable disease, defined as ≥ 1 measurable lesion defined by RECIST criteria

          -  Not amenable to surgical resection or external-beam radiotherapy or refractory to
             radioiodine therapy

          -  No untreated brain metastasis

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  ANC ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9.0 g/dL

          -  Creatinine &lt; 1.5 mg/dL

          -  Total bilirubin ≤ 1.0 times upper limit of normal (ULN)

          -  ALT and AST ≤ 3.0 times ULN

          -  No known hypersensitivity to the study drug

          -  No serious uncontrolled systemic intercurrent illness (e.g., infection or poorly
             controlled diabetes)

          -  No history of significant neurological or mental disorder, including seizures or
             dementia

          -  No other malignancy within the past 5 years except for carcinoma in situ of the cervix
             or nonmelanomatous carcinoma of the skin

          -  No active uncontrolled cardiac disease

          -  No myocardial infarction within the past 12 months

          -  Able to take oral medication

          -  No active peptic ulcer disease

          -  Must have patient compliance and geographic proximity for adequate follow-up

        PRIOR CONCURRENT THERAPY:

          -  At least 30 days since prior mTor-inhibitor therapy (e.g., temsirolimus) or
             non-hormonal anticancer therapy

          -  At least 2 weeks since prior and no concurrent P-glycoprotein, CYP3A4, and CYP3A5
             inhibitors or inducers

          -  No prior surgical procedure affecting absorption

          -  No other concurrent systemic chemotherapy, investigational drug, or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung Chul Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang, Gyeonggi-do</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>712-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center - Korea</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin Medical Center Gospel Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>insular thyroid cancer</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>stage III follicular thyroid cancer</keyword>
  <keyword>stage III papillary thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

